Shares of Century Therapeutics Inc IPSC zoomed by 20.74% to $1.63 per share on Wednesday, which is the highest price move in nearly a month since Oct. 1. The shares also rose the most in over 11 months since Dec. 6, 2023, in a single day.
What Happened: On Wednesday, Casdin Capital acquired an additional 1,380,000 shares in Century Therapeutics raising its stake by nearly 43% in the biotechnology company, as per an SEC filing.
After the transaction, Casdin Capital owns a total of 4,592,316 shares, or 5.4% in Century Therapeutics. According to the filing, Century shares were acquired for $1.35 apiece. Century Therapeutics represents 0.12% of Casdin’s portfolio after the transaction.
Why It Matters: Century shares jumped by nearly 21%, the most in a single day since Dec. 6, 2023, when it had jumped by 36% after the transaction.
Casdin Capital, LLC, a New York-based investment firm, specializes in biotechnology investments. With a $1.5 billion equity portfolio, its top holdings include BioLife Solutions Inc (BLFS) and Sarepta Therapeutics Inc (SRPT).
Image via Unsplash
Read Next:
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.